BD-368-2
An anti-RBD (SARS-CoV-2 Spike) monoclonal antibody.
General information
BD-368-2 is a human monoclonal antibody (IgG1) from a COVID-19 convalescent patient. It was identified by high-throughput single B cell sequencing. The antibody binds RBD (SARS-CoV-2 Spike) and potently neutralizes the virus in vitro. BD-368-2 blocks all ACE2 binding sites. It displayed efficacy in animal model studies (Cao et al., 2020; Du et al. 2020).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells
Spike protein Novel compound Biophysical assay Protein factor Animal model In vitro Antibody Screening |
In vitro biophysical assay; Vero E6 cells; Huh-7 cells; hACE2 mice; (VSV) SARS-CoV-2 Spike-pseudotyped virus; SARS-CoV-2 strain BetaCoV/Wuhan/AMMS01/2020 | 41.58 | The antibody bound SARS-CoV-2 Spike RBD and neutralized the virus in vitro. It antibody displayed prophylactic and therapeutic efficacies in a murine model. |
May/17/2020 |
|
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy
Spike protein Cryo-EM Crystallization Biophysical assay Protein factor Animal model In vitro Mechanism Antibody |
In vitro biophysical assay; Huh-7 cells; Golden hamsters; (VSV) SARS-CoV-2 Spike-pseudotyped virus; SARS-CoV-2 strain SARS-CoV-2/WH-09/human/2020/CHN | 41.58 | The antibody bound SARS-CoV-2 Spike RBD and neutralized the virus in vitro. It displayed prophylactic and therapeutic efficacies in a murine model (based on observations of lung pathology, weight loss and viral load). |
Sep/14/2020 |
AI-suggested references
| Link | Publication date |
|---|---|
|
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells
|
Oct/14/2020 |
